(0.61%) 5 159.00 points
(0.19%) 38 748 points
(0.68%) 16 267 points
(0.50%) $78.50
(5.14%) $2.25
(0.89%) $2 329.20
(3.47%) $27.62
(-0.11%) $964.25
(-0.07%) $0.928
(-0.42%) $10.83
(-0.13%) $0.796
(-0.14%) $91.32
0.00% ¥ 35.00
Live Chart Being Loaded With Signals
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group...
Stats | |
---|---|
Tagesvolumen | 5.21M |
Durchschnittsvolumen | 4.06M |
Marktkapitalisierung | 2.47B |
EPS | ¥0 ( 2023-05-11 ) |
Last Dividend | ¥10.00 ( 2022-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 0.0000000 |
ATR14 | ¥4.97 (0.00%) |
Volumen Korrelation
Nichi-Iko Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Nichi-Iko Pharmaceutical Korrelation - Währung/Rohstoff
Nichi-Iko Pharmaceutical Finanzdaten
Annual | 2022 |
Umsatz: | ¥16 907.73B |
Bruttogewinn: | ¥3 331.59B (19.70 %) |
EPS: | ¥128.01 |
FY | 2022 |
Umsatz: | ¥16 907.73B |
Bruttogewinn: | ¥3 331.59B (19.70 %) |
EPS: | ¥128.01 |
FY | 2022 |
Umsatz: | ¥179.06B |
Bruttogewinn: | ¥3.97B (2.21 %) |
EPS: | ¥-1 500.00 |
FY | 2021 |
Umsatz: | ¥188.22B |
Bruttogewinn: | ¥21.25B (11.29 %) |
EPS: | ¥-65.28 |
Financial Reports:
No articles found.
Nichi-Iko Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
First Dividend | ¥12.00 | 2008-05-27 |
Last Dividend | ¥10.00 | 2022-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 29 | -- |
Total Paid Out | ¥380.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.02 | -- |
Div. Sustainability Score | 9.48 | |
Div.Growth Potential Score | 2.03 | |
Div. Directional Score | 5.75 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7976.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7212.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6458.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5464.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4461.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3641.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1716.T | Ex Dividend Knight | 2024-06-27 | Annually | 0 | 0.00% | |
9308.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0400 | 1.500 | 9.20 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0137 | 1.200 | 9.54 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0717 | 1.500 | -0.315 | -0.472 | [0.1 - 1] |
payoutRatioTTM | 0.555 | -1.000 | 4.45 | -4.45 | [0 - 1] |
currentRatioTTM | 1.440 | 0.800 | 7.80 | 6.24 | [1 - 3] |
quickRatioTTM | 0.617 | 0.800 | -1.074 | -0.859 | [0.8 - 2.5] |
cashRatioTTM | 0.584 | 1.500 | 7.86 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.185 | -1.500 | 6.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 92.82 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 119.18 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 86.82 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.474 | -1.500 | 8.11 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.202 | 1.000 | 9.97 | 9.97 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0414 | 1.000 | -1.172 | -1.172 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.121 | 1.000 | -0.438 | -0.438 | [0.2 - 2] |
assetTurnoverTTM | 0.344 | 0.800 | -1.042 | -0.833 | [0.5 - 2] |
Total Score | 9.48 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.478 | 1.000 | -0.0527 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0717 | 2.50 | -0.202 | -0.472 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 86.82 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 119.18 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.555 | 1.500 | 4.45 | -4.45 | [0 - 1] |
pegRatioTTM | 0.00441 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0651 | 1.000 | -0.872 | 0 | [0.1 - 0.5] |
Total Score | 2.03 |
Nichi-Iko Pharmaceutical
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.